SCYNEXIS Overview 2010: Fully Integrated Drug Discovery CRO Solutions

SCYNEXIS® Proprietary and Confidential Information

Fully-Integrated Drug Discovery

& Development Solutions

March 31, 2010

SCYNEXIS delivers integrated, efficient and innovative drug discovery and development SOLUTIONS to our global health and pharmaceutical partners. Our record of success is exemplified by the delivery of 11 pre-clinical drug candidates over the last five years. Additionally, SCYNEXIS has developed the chemical manufacturing process for a customer’s NDA. We are registered with and inspected by both the FDA and DEA.

SCYNEXIS provides Fully-Integrated Contract Research SOLUTIONS including:● Medicinal Chemistry● Lead Optimization● Computational Chemistry● ADMET-PK● Bioanalysis● Process / cGMP Chemistry● Analytical Chemistry


About SCYNEXIS

We provide more than justcompounds…

We provide you with DRUGS

● Founded in July 2000 in Research Triangle Park, NC● Former Sanofi-Aventis (Rhône-Poulenc) Researchers● 140+ Team Members across the 120,000 ft2 Facilities● Experienced Leadership

◆ Merck, GSK, Sanofi-Aventis, Pfizer, BMS, AstraZeneca, BASF, Lilly, Trimeris, DSM

● Unique Risk/Reward Partnering Business◆ Profitable Service Business◆ Product and Partnership Upsides

About SCYNEXIS: Founding & Personnel


SCYNEXIS: By the Numbers

● 140+ Employees Across Two Campuses17+ Years of Experience (Average)50% Ph.D.’s on Chemistry Teams

● 120,000 ft2 facilities in RTP, NC64 Fume HoodsLargest “Chemistry House” in SoutheastLC/MS/MS, HPLC, GC/MS, NMR, DSC


● 100+ Clients Spanning the Globe Virtual/Biotech/Midsize/Top 25MedChem/Process/DMPK

● Strong Financials & Proven Success$32.5M for 2008Service/Milestones/Royalties80% CAGR of Revenues11 Preclinical Candidates

Focus on TeamworkIntegrated Project Management &

Weekly Client Updates

Customer Service Excellence>90% Return Rate of Business

Proven Success with Proven Success with SCYNEXISSCYNEXIS

CLIENT

Why SCYNEXIS?

Drug Discovery & Development ExpertiseFully-integrated Research Units (DMPK-MedChem-GMP A PI)

Concept to Marketed Drugs~17 years Experience per FTE

Integrity & ConfidentialityUS Operations, Data Security, Clients own IP

Innovation & CreativityWorld-class Scientists & Proven Track Record

11 PCC’s, multiple IND’s/NDA’s

11 Compounds Nominated 11 Compounds Nominated as Clinical Candidatesas Clinical Candidates


Publicly Disclosed SCYNEXIS Clients

*All publicly disclosed prior to January 2010


● SCYNEXIS’ Goal◆ Develop Long-Term Relationships via Dedicated Proje ct Resources

Working with SCYNEXIS

Dedicated Project TeamProject LeaderMedicinal ChemistsComputational ChemistsAnalytical & Bioanalytical ChemistsDMPK & ToxicologyBiochemistry & Screening ScientistsProcess Chemists

● Key Attributes◆ Flexibility of the Team◆ Multiple Scientific Disciplines◆ Seamless Functional Transitions◆ 1 – 35 FTE’s

Fully-integrated Research Units

Success with SCYNEXIS

Innovative Drug Pipeline Solutions


● Structure-aided Lead Optimization Programs◆ CNS Target – Multiple Clinical Candidates for Sepracor◆ Anti-Fungal* – 3 Clinical Candidates for Merck◆ Ion Channel Blocker* – Ophthalmology Compound for Merck◆ Anti-Parasitic – Potent Compound for Merck◆ Nuclear Hormone Receptors – Novel Ligands for GSK◆ Anti-inflammatory – Scaffold-hopping for Teijin◆ GPCR Kinase 2 – Novel Series of Inhibitors Generated◆ Oncology Target – Novel, Potent Inhibitor Templates◆ Pain – Novel Prodrug Series Identified

* Natural Product Optimization


● Classical Medicinal Chemistry Programs◆ IP Generation Engine

■ Anti-Parasitics – Novel, Safer Compound Identified. Now in Phase III.

■ Anthelmintics – Novel Series Invented and Compound Identified■ CNS – Novel Series Invented and 4 Patent Applications Submitted to

USPTO■ SCYNEXIS Medicinal Chemists Solely Responsible for IP Development

◆ Pharmacophore Based Screening◆ Application of New Chemistry to Old Templates


● Knowledge Base of Chemical and Clinical Development◆ SCYNEXIS team members have assembled >20 IND packag es

■ FUZEON: Anti-HIV Drug from Discovery to NDA■ Cystic Fibrosis Drug from Discovery to Phase Ib■ Anti-HCV Drug from Discovery to Phase II■ Chemical Process Developed for NDA

SCYNEXIS Medicinal Chemistry


Dr. Mike PeelDirector, Medicinal [email protected]

The SCYNEXIS Medicinal Chemistry Team

Medicinal Chemistry ExpertiseGlobally Recognized Excellence

Experienced LeadershipGSK, AstraZeneca, Sanofi-Aventis,

Pfizer, Lilly, Merck

51 Team Members27 Ph.D’s / Medicinal / Computational

Broad ExpertiseMulti-factorial Optimization,

Parallel Synthesis/Purification, KIT TM

Numerous Therapy Areas

CLIENT

Computational & Cheminformatics SupportHEOS® Data Management & Collaboration Software Suite


Medicinal Chemistry Expertise

● Broad range of expertise in multiple therapeutic areas including:

◆ Natural Product Optimization◆ Antifungals◆ Antivirals◆ Antibacterials◆ Antiparasitics◆ Nuclear Hormones◆ Ion Channels

◆ Oncology◆ Kinases◆ Inflammation◆ Pain◆ Central Nervous System (CNS)◆ Opththalmology◆ Prodrug Design

SCYNEXIS’ Medicinal Chemistry Expertise Areas

Solubility, stability

Potency, SelectivityMetabolism, PK

Potency, PKEfficacy, Tox.

Potency,SelectivityPotency

Potency, efficacyCNS penetration

Peptide

Heterocycle Ion ChannelComplex Natural Product

Kinase Inhibitor

Nuclear Receptor LigandNatural Product

SCYNEXIS MedChem

SCYNEXIS DMPK & Biology


Dr. Steve WringDirector, DMPK-Tox & [email protected]

The SCYNEXIS DMPK & Biochemistry Team

Broad Areas of ExpertiseFull Support for Discovery - Development

Experienced LeadershipLarge and Small Pharma/Biotech Experience

& Research Investigators

17 Team Members7 Ph.D.’s / 3 MSc / 7 BSc’s

5 LC/MS/MS SystemsCell Culture Suite

Multiple Concurrent ProgramsHits-to-Lead to Lead-Opt

Lead-Opt to Candidate SelectionExploratory Development

CLIENT

Supporting Broad Healthcare InitiativesNeglected Diseases, CNS, Anti-Infectives, Oncology,

Metabolic Diseases, Ophthalmology, Pain, Animal Hea lth


Full Discovery DMPK Function Integrated into MedChe m Decision Process

SCYNEXIS DMPK

Provide Fast & Efficient Decision Support to Medici nal Chemists for Rapid Lead Optimization & Candidate Selection

● Discovery DMPK◆ Permeability◆ Transporters◆ Metabolic stability◆ CYP450 inhibition◆ Mechanistic metabolism ◆ Metabolite ID◆ Protein binding◆ Tissue distribution◆ Animal PK◆ Pilot toxicity studies

● Bioanalysis◆ Method Development◆ Validation◆ Rapid Sample Analysis◆ Pharmacokinetics◆ High Sensitivity ◆ In Vitro DMPK Assays◆ Discovery PK Studies◆ Metabolite Identification◆ Clinical Support

SCYNEXIS DMPK Bioanalytical

State-of-the-art facility with 5 dedicated LC-MS/MS Systems

API3000 (3) / API4000 (1) / 4000 Q-Trap (1)


● Integrated In Vitro Pharmacology & Biochemistry◆ Genetic confirmation of drug target

◆ Activity based kinase screening (Luminescence)◆ Chaperone binding assays

◆ Cytokine release assays

◆ Protein association studies (inc. Y2H)◆ Cellular cytotoxicity assays

◆ Phenotypic screens for parasiticides

◆ Receptor assays (Including GPCR & ligand-gated ion channels)◆ Ion channels

SCYNEXIS Biology and Biochemistry

Target Validation and Biological Support for Drug Discovery Projects


SCYNEXIS Biology and Biochemistry

● Screening◆ New target screening, forward/reverse genetics (RNAi)◆ Assay development/optimization◆ Enzymatic, binding and functional assays

■ Including medium throughput screening on ion channels, GPCR’s & kinases◆ Cell culture and high content screening modalities◆ Whole organism assays (C. elegans, drosophila, trypanosomes)

● Core Capabilities◆ Extensive liquid handling capabilities for compound management◆ Automated screening methods◆ Fluorescence microscopy/ cell morphology◆ ELISA◆ Gene manipulation and protein expression◆ Enzymology◆ Radioisotope license in progress


SCYNEXIS Process Chemistry


Dr. Bob Rodebaugh Director, Process & Analytical [email protected]


The SCYNEXIS Process Team

Process Development FocusedExpert Problem Solvers

Developed Chemical Process for NDA

Experienced LeadershipMerck, GSK, Aventis, Pfizer, BASF, DSM, Lilly

24 Team Members12 Ph.D.’s / 13 Process Chemists /

11 Analytical Chemists

40+ Global Clientele~ 500 Completed Projects

81 in 2008, 85 in 2009$1K - $2 M Range

CLIENT


FDA AuditedPAI – October 2009No Observations

No 483’s

SCYNEXIS Process Development

● Rapid Turnaround & Efficient Custom SynthesisIntermediates

Reference Standards

Process Impurities

Analog Synthesis

Preparative Chromatography

High Pressure Reactions

● Chemical Development ExpertiseScale-Up of Medicinal Chemistry Routes

Novel Route “Scouting” & Development

Route & Process Optimization

Developed Process for NDA


SCYNEXIS cGMP Manufacturing

● FDA Registered, Inspected● Controlled Access● Pre-Clinical Through Phase Ill● World-Class Facilities

◆ Chemical Development Labs◆ Kilo Scale Lab for non-GMP Scale up◆ GMP Kilo Scale Manufacturing Suite

● Small Scale Commercial Manufacturing◆ PAI October 2009 – No Observations/483s

● State of the Art Equipment◆ 25L to 200L Capacity

♦ Glass Fixed Reactors, -80 to +200 °C ♦ Huber Temperature Controllers

◆ Dedicated Air Handlers◆ Parr 2 Gallon Pressure Reactor◆ Preparative Chromatography Systems


SCYNEXIS Analytical R&D

● Capabilities & Expertise1:1 Ratio of Process : Analytical

GMP/GLP Method Development by Ph.D. Level Scientists

Validation & Stability Studies to ICH GuidelinesImpurity, Degradation Product, Structural Identification

● Key Analytical Instrumentation29 HPLC Systems (Waters/Agilent)

PAD, ELSD, UV-Vis, Fluorescence, UPLC

12 LC/MS & LC/MS/MS Systems

3 GC/MS & GC/FID Headspace/Liquid

GMP 400 & 500 MHz Varian NMR4 Semi-prep Chromatography Systems

DSC/TGA, K-F, TOC, FTIR


HEOS® Drug Development Collaboration Tool

Secure web-based portal for real-time data sharing and communication

N

N

O

Ar

NH2

PDF

Third-Party Software

SDFTXT

…


SCYNEXIS Quality Systems

GMP Regulatory MissionEnsuring Quality, Purity & Strength

FDA AuditedGeneral Inspection & Pre-Approval Inspection (PAI)

October 2009No Observations, No Form 483s Issued

FDA Regulatory Guidelines21 CFR Parts 210 & 211

GMP FoundationsMaster Validation Plan / SOPs & DocumentControl / Production & Testing Controls /

Project Documentation

GMP

GMP FoundationsQualified Personnel / Qualified Equipment /

Validated Software / Facility Design


SCYNEXIS Values

IntegrityWe will treat all employees with respect

and ethically conduct business

InnovationWe will continuously generate creative solutions to

both technical and business challenges.

TeamworkWe will work together towards

achieving company goals

SafetySafety concerning employees, customers, public

and the environment. Safety impacts everyaction and decision

SCYNEXIS

QualityWe will deliver superior products and services exceeding our customer’s

expectations


SCYNEXIS is a fully-integrated drug discovery & development company:

◆ Experienced & Highly-Skilled Personnel◆ Proven Record of Success◆ Delivered 11 Preclinical Candidates (IND’s)◆ State of the Art Facilities◆ Integrated Drug Development Solutions◆ FDA & DEA Registered◆ Commercial API Supplier – PAI October 2009◆ Rapid DMPK / Lead-Optimization Studies◆ Dedicated Project Management◆ Desire Long-Term Relationships

SCYNEXIS Summary

Providing more than just compounds… SCYNEXIS provide s you with DRUGS!

Terry Marquardt Executive Director, Market Development

[email protected]

Mike Peel, Ph.D. Director, Medicinal [email protected]

Steve Wring, Ph.D. Director, DMPK

[email protected]

Bob Rodebaugh, Ph.D. Director, Process, GMP & Analytical Chemistry

[email protected]

Bryce Chaney, M.B.A.Market Development Manager, Process & Analytical Ch emistry

[email protected]

SCYNEXIS Inc.3501-C Tricenter Blvd

Durham, NC 27713www.scynexis.com

Contact Information

www.scynexis.com


Thank You!

Documents

SCYNEXIS Overview 2010: Fully Integrated Drug Discovery CRO Solutions